This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Extent, Consequences, and Management

David Blumenthal, MD, MPP

JAMA. 1992;268(23):3344-3349.

Abstract
Academic-industry relationships in the life sciences remain controversial. The available evidence suggests that such relationships have both benefits and risks for involved parties. Benefits include additional support of academic research, income for academic health centers, the potential for increased scientific and commercial productivity in both industries and universities, and enhancement of the educational experiences of students and fellows. Risks include an increase in secrecy in academic environments and damage to public support for the life science enterprise. The balance of known benefits and risks suggests that academic-industry relationships should be permitted and even selectively promoted. However, there is also a need for enhanced vigilance on the part of academic institutions and government to reduce risks posed by certain types of arrangements, especially those involving human subjects. Enhanced vigilance should include disclosure of all academic-industry relationships by life science faculty.

(JAMA. 1992;268:3344-3349)

Author Affiliations
From the Health Policy Research and Development Unit, Massachusetts General Hospital, and the Harvard Medical School, Boston, Mass.

Footnotes
Reprint requests to Health Policy Research and Development Unit, Massachusetts General Hospital, Boston, MA 02114 (Dr Blumenthal).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry
Mello et al.
NEJM 2005;352:2202-2210.
ABSTRACT | FULL TEXT  

Inside Information: Financial Conflicts of Interest for Research Subjects in Early Phase Clinical Trials
Helft et al.
JNCI J Natl Cancer Inst 2004;96:656-661.
ABSTRACT | FULL TEXT  

Academic-Industrial Relationships in the Life Sciences
Blumenthal
NEJM 2003;349:2452-2459.
FULL TEXT  

Proprietary Products and Research: The Proponents' View
Richardson et al.
Pediatrics 1998;102:401-403.
FULL TEXT  

Research Publications Involving Proprietary Products: Science, News, or Advertising?
Kanter
Pediatrics 1998;101:468-468.
FULL TEXT  

The Clinical Introduction of Genetic Testing for Alzheimer Disease: An Ethical Perspective
Post et al.
JAMA 1997;277:832-836.
ABSTRACT  

Participation of Life-Science Faculty in Research Relationships with Industry
Blumenthal et al.
NEJM 1996;335:1734-1739.
ABSTRACT | FULL TEXT  

Relationships between Academic Institutions and Industry in the Life Sciences -- An Industry Survey
Blumenthal et al.
NEJM 1996;334:368-374.
ABSTRACT | FULL TEXT  

Ethical Issues in Sponsored Clinical Research
Barnett
JDR 1995;74:1129-1132.
ABSTRACT  

Institutional Conflict of Interest
Emanuel and Steiner
NEJM 1995;332:262-268.
FULL TEXT  

Independent Investigators and For-Profit Companies: Guidelines for Biomedical Scientists Considering Funding by Industry
Chren
Arch Dermatol 1994;130:432-437.
ABSTRACT  

Medicine at Center Stage
Kassirer
NEJM 1993;328:1268-1269.
FULL TEXT